Background Despite the greater prevalence of familial hypercholesterolemia (FH) in
subjects with ischemic heart disease (IHD), premature IHD, and severe …

Atherosclerosis is a chronic vascular inflammatory disease associated to oxidative stress
and endothelial dysfunction. Oxidation of low‐density lipoprotein (LDL) cholesterol is one of …

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on
the Management of Blood Cholesterol: Executive Summary: A Report of the American …

The recommendations listed in the present guideline are, whenever possible, evidence
based. An initial extensive evidence review, which included literature derived from research …

Background Familial hypercholesterolemia is characterized by an elevated level of low-
density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic …

Every 5 years, the JAS publishes guidelines for the treatment of dyslipidemia and
atherosclerosis. To date, this society has released four such guidelines. Since 2007, the JAS …

Background Evolocumab is a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels …

Material de distribuição exclusiva à classe médica. Os Arquivos Brasileiros de Cardiologia
não se responsabilizam pelo acesso indevido a seu conteúdo e que contrarie a …

Evidence that elevated lipoprotein (a)(Lp [a]) levels contribute to cardiovascular disease
(CVD) and calcific aortic valve stenosis (CAVS) is substantial. Development of isoform …

Background Evolocumab, a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …